Newronika, an Italian firm specializing in advanced deep brain stimulation (DBS) technology, has successfully closed a €13.6M Series B funding round. The funds will support its adaptive DBS platform capable of adjusting therapy in real-time based on patient data, marking significant progress in neuromodulation treatments. Backed by notable investors, including Fondazione ENEA Tech e Biomedical, the company aims to revolutionize treatment for movement disorders, particularly benefiting Parkinson's patients. With various approvals and active research partnerships, Newronika is poised for impactful clinical development and commercial growth in the neuromodulation sector.
Milan-based Newronika has closed a €13.6M Series B funding round, advancing their adaptive deep brain stimulation platform for neurological disorder treatment.
Collection
[
|
...
]